Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new £1.5M grant from the Medical Research Council (MRC) to the Powrie Group at the Kennedy Institute of Rheumatology will help define different pathotypes of inflammatory bowel diseases that could lead to better and more focused treatments for patients.

Woman holding her stomach appearing to be in pain

The intestine is one of the largest immune organs in the body. When healthy, it is regulated by a complex communication network which ensures that the intestinal immune cells peacefully co-exist with the large number of microbes that inhabit the gut.

When there is disruption to any of the communication pathways, the wall of the intestinal wall can become inflamed and inflammatory bowel diseases (IBDs), encompassing Crohn's disease (CD), ulcerative colitis (UC) and IBD unclassified (IBDu), can develop.

There is no cure for IBD and patients can go through unpredictable periods of relapse and remission. Genes, diet and other environmental factors all play a part meaning the disease is never the same for any patient and the response to therapies can vary, with more than 1 out of 2 patients not responding to treatment in the long-term. For this reason, personalised therapies are not standard practise for IBD.

"In a previous study we were able to group patients with IBD, that do not respond well to current therapies, based on their cellular and molecular characteristics or 'pathotype'", said Professor Dame Fiona Powrie, Director of the Kennedy Institute of Rheumatology. "The MRC funding will enable us build on this work and characterise these IBD pathotypes in more detail. By understanding the pathotypes of different patient groups, we move towards being able to discover and direct new therapies to those most likely to benefit."

Read the full story on the Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences website

Similar stories

EAVI2020: The Quest for an HIV Vaccine

In this long read published to coincide with International AIDS Day, we explore how an international collaboration – of which the University of Oxford is a key partner – has boosted HIV vaccine research. We thank our partners at Imperial College London for allowing us to reproduce and abridge this article.

New SMRU building opened in Thailand to provide health care to marginalized populations

The inauguration of a new joint Shoklo Malaria Research Unit (SMRU) and Borderland Health Foundation (BHF) Building took place in Mae Ramat, Thailand, this week.

Smoking increases the risks of 56 diseases in Chinese adults

Smoking increases the risks of 56 diseases and kills more than one million adults in China each year from 22 different causes, according to new research published in The Lancet Public Health.

Success for Oxford researchers in The Genetics Society 2023 Awards

Researchers from Department of Physiology, Anatomy and Genetics, Radcliffe Department of Medicine and Nuffield Department of Population Health have been recgonised in The Genetics Society 2023 awards.

New Studentship honours Enzo Cerundolo

A new Studentship has been announced in memory of the late MRC HIU Director and MRC WIMM Group Leader.